Corpus Intelligence IC Memo — OCHSNER LSU HEALTH MONROE 2026-04-26 04:01 UTC
IC Memo — OCHSNER LSU HEALTH MONROE
Investment Committee Memorandum | LA | 84 beds | Grade C | EBITDA uplift $6.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

OCHSNER LSU HEALTH MONROE

CCN 190011 | nan, LA | 84 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

OCHSNER LSU HEALTH MONROE is a 84-bed under-performing / distressed in nan, LA with $85.1M in net patient revenue and a -100.0% operating margin. The hospital serves a payer mix of 9.0% Medicare, 2.8% Medicaid, and 88.2% commercial.

Thesis: Turnaround. Our ML models identify $6.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -100.0% to -93.0% (+736bps).

Net Revenue HCRIS$85.1M
Current EBITDA COMPUTED$-85.4M
Operating Margin COMPUTED-100.0%
Occupancy HCRIS63.4%
Revenue / Bed COMPUTED$1.0M
Net-to-Gross HCRIS16.3%
Distress Probability ML42.7%

2. Market Context & Competitive Position

212
LA Hospitals
-3.5%
State Median Margin
50
Comparable Hospitals

LA has 212 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of -100.0% places it below the state median. Among 50 size-comparable peers (42-168 beds), the median margin is -3.1%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (42-168), prioritizing same-state peers. 50 hospitals in the comp set.

HospitalStateBedsRevenueMargin
OCHSNER LSU HEALTH MONROE (Target)LA84$85.1M-100.0%
THIBODAUX REGIONAL HEALTH SYSTLA164$244.9M-1.7%
TERREBONNE GENERAL HEALTH SYSTLA139$230.6M-8.3%
OCHSNER MEDICAL CENTER - KENNELA115$193.8M-2.9%
ST. PATRICK HOSPITALLA100$189.4M-7.4%
OPELOUSAS GENERAL HOSPITALLA151$168.5M-12.7%
UNIVERSITY HOSPITAL & CLINICSLA52$158.9M-33.4%
OCHSNER MEDICAL CENTER -NORTHSLA150$107.3M-5.7%
IBERIA MEDICAL CENTERLA133$107.0M1.3%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $6.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.8M+210bp18mo
Cost to Collect4.5%2.5%$1.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.7M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.0M+122bp9mo
Clean Claim Rate88.0%96.0%$54K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.8M
Cost to Collect
$1.7M
Denial Rate Reduction
$1.7M
A/R Days Reduction
$1.0M
Clean Claim Rate
$54K
Total EBITDA Uplift$6.3M
Current EBITDA$-85.4M
+ RCM Uplift+$6.3M
Pro Forma EBITDA$-79.2M
Current Margin-100.0%
Pro Forma Margin-93.0%
WC Released (1x)$3.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-131.4M$-500.8M0.00x-100.0%
Base (11x exit)10.0x11.0x$-131.4M$-593.6M0.00x-100.0%
Bull Case9.0x11.0x$-118.3M$-615.6M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-118.3M$-706.4M0.00x-100.0%
Bear Case11.0x10.0x$-144.5M$-489.4M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-144.5M$-585.3M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 50 hospitals with 42-168 beds
  • Same-state prioritization (n=51)
  • Comp margins: P25=-24.3% / P50=-3.1% / P75=4.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.